Paper Details

  1. Home
  2. Paper Details

High-dose cisplatin and vinblastine infusion with or without radiation therapy in patients with advanced non-small-cell lung cancer.

Author: AllegraJ C, BarnesG R, BlumenreichM S, EpremianB E, GentileP S, JoseB, KubotaT T, RichmanS P, SherrillE J, WoodcockT M

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated the effectiveness of a chemotherapy regimen using cisplatin and vinblastine in 47 patients with advanced non-small-cell lung cancer (NSCLC). The treatment resulted in a response rate of 28% and a median survival of 22 weeks. Patients who responded to chemotherapy had a longer median survival (63.2 weeks) compared to those who didn't respond (17.9 weeks). The study also evaluated the effect of radiation therapy, finding no significant survival benefit for those who received it. The chemotherapy regimen was associated with significant side effects, including low white blood cell count, low platelet count, infections, nausea, vomiting, hearing loss, and nerve damage. The study concludes that this particular chemotherapy regimen is not recommended for standard treatment of NSCLC due to its significant toxicity and lack of improved survival or response rates.
Paper Details　
Original Abstract of the Article :
Non-small-cell lung cancer (NSCLC) patients with locally advanced or metastatic measurable disease were given a combination of cisplatin, 200 mg/m2 divided in five daily doses, and simultaneously, vinblastine, 7.5 mg/m2 as a continuous intravenous (IV) infusion over five days. Five courses of chemot...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.1987.5.11.1725

データ提供：米国国立医学図書館（NLM）

Combating Advanced Non-Small Cell Lung Cancer: A Challenging Journey

This study, like a determined caravan traversing a challenging terrain, explores the effectiveness of high-dose cisplatin and vinblastine infusion, with or without radiation therapy, in treating patients with advanced non-small cell lung cancer (NSCLC). The researchers studied 47 patients with locally advanced or metastatic NSCLC, administering five courses of chemotherapy followed by randomization to either radiation therapy or observation only. The study revealed that while the regimen was associated with significant side effects, it resulted in a modest response rate and did not offer any major survival benefits. The authors concluded that this treatment regimen is not recommended for standard treatment of NSCLC.

The Limitations of High-Dose Cisplatin and Vinblastine

The study underscores the challenges of treating advanced NSCLC. While the regimen showed some promise, the significant side effects and limited survival benefits suggest that it is not a viable option for standard treatment. The authors' conclusion reflects the need for continued research to develop more effective and tolerable treatment strategies for this challenging disease.

Navigating the Shifting Sands of Cancer Treatment

This study highlights the ongoing search for effective and tolerable treatments for advanced NSCLC. While the regimen explored in this study was not successful, it provides valuable insights for future research efforts. Continued investigation is essential to improve the treatment outcomes for patients with this complex and challenging disease.

Dr.Camel's Conclusion

This study reveals the complexities of treating advanced non-small cell lung cancer. The high-dose cisplatin and vinblastine regimen, while not without merit, ultimately proved to be too toxic with limited benefit. This underscores the need for continued research to develop better treatments for this challenging disease.
Date :
  1. Date Completed 1987-12-23
  2. Date Revised 2017-02-10
Further Info :

Pubmed ID

2824706

DOI: Digital Object Identifier

10.1200/JCO.1987.5.11.1725

Related Literature

Article Analysis
・Effective treatment of lung cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.